Peloton Interactive Goldman Sachs Raises Price Target on Fitness Stock Amid Improved Guidance SpaceX IPO Would Early Investors Be Set for Life A Look at the Potential AI Transformation Insights Seth Ketrons Findings Signal Shifts in Business and Consumer Dynamics Reliance Industries Sets June 19 for 49th AGM Announces FY26 Dividend Record Date SIPs Not to Blame for Rupee Weakness Says Samir Arora in Response to Jefferies Report Ferrari Shares Dip After Unveiling First Electric Vehicle Market Reaction Suggests Caution BMRA Q1 2026 Earnings Loss of 044 Per Share Amid No Revenue Disclosure ONC Q4 2025 Earnings EPS Misses Estimates by Wide Margin Stock Slides 25 WKHS Q1 2026 Earnings Deepening Losses Amid Operational Transition BOOM Q1 2026 Earnings EPS Surprises to the Upside Despite Loss Corcept Therapeutics CORT Q1 2026 Earnings Severe Earnings Miss Overshadows Operational Developments Sigma Lithium Q1 2026 Earnings Strong EPS Beat Amid Lithium Market Tailwinds EZGO Technologies Drops Sharply Testing Key Support at 140 Lulus Fashion Lounge LVLU Sees 39 Decline Evaluating Key Support and Resistance Levels Real Asset Acquisition Corp RAAQ Slides 27 as SPAC Selling Pressure Intensifies CAAS Holds Near Support Amid Modest Gains UL Solutions Holds Steady Near 100 as Consolidation Continues Standard Chartered Plans to Cut Over 15 of Corporate Functions Roles Targets Higher Returns by 2028 ST Bancorp Inc STBA Q1 2026 Earnings Earnings Beat Expectations with EPS of 094 Melar Acquisition Corp I MACI Holds Steady Near 1085 as SPAC Trading Remains Subdued OXLCN Q4 2025 Earnings EPS Misses Estimates but Stock Edges Higher BEAM Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Market Response HOUR Q4 2024 Earnings Loss Per Share of 004 Reported Amid Quiet Trading NACCO Industries NC Q1 2026 Earnings EPS of 117 Reported Amid Limited Disclosure STX Q1 2026 Earnings EPS Surges Past Estimates with Strong Operational Execution AptarGroup Q1 2026 Earnings EPS Beats Estimates by 233 Shares Edge Higher TVTX Q1 2026 Earnings EPS Miss as PreRevenue Biotech Ramps Up Spending